Clinical Trial Detail

NCT ID NCT02203773
Title Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

acute myeloid leukemia

Therapies

Decitabine + Venetoclax

Azacitidine + Venetoclax

Age Groups: senior

No variant requirements are available.